Teijin Pharma Of Japan To Apply For Clinical Trial Approval Of Gout Drug In China
This article was originally published in PharmAsia News
Teijin Pharma will apply for clinical trial approval for Uloric (febuxostat, TMX-67) to treat gout and hyperuricemia in China. The Tokyo-based drug and medical maker plans to conduct the trials in China using clinical data used in Europe. Teijin also looks for local Chinese contract research organizations and aims to launch the drug in China through its wholly owned subsidiary Teijin Pharma Shanghai Consulting. Teijin jointly launched Uloric in the U.S. with Tekeda Pharmaceutical North America this March and plans a European market launch this autumn under Adenulic along with French pharmaceutical company Ipsen. This May, Teijin signed grant exclusive licensing rights to Astellas to develop and market the drug in Taiwan. (Click here for more - Japanese language
You may also be interested in...
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.